Fresenius Medical Care hits four-month high, shares approach 42 euros on Xetra
23.06.2026 - 08:35:06 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 08:33.
Fresenius Medical Care (DE0005785802) extended its recovery at the start of the week, with the shares on Xetra touching 41.58 euros on Monday, the highest level since February, according to a dpa-AFX broker note cited by MarketScreener.The MarketScreener summary of the dpa-AFX report states that Goldman Sachs analyst Richard Felton expects another solid improvement in operating profit in the upcoming quarterly figures in early August.
Goldman Sachs stays constructive
The dpa-AFX broker commentary highlights that Goldman Sachs is optimistic about the next earnings release, with Felton expecting operating profit to improve again versus the prior year quarter.The detailed note reproduced by MarketScreener underlines that the early August report is in focus for the dialysis specialist.
In the United States, Felton still sees sluggish growth in treatment volumes on a same-market treatment growth basis, which he describes as a key factor for a sustained re-rating of the shares.The broker commentary points out that U.S. volumes have moved slightly into positive territory in 2026 but remain an area watched closely by analysts.
Analyst consensus and valuation picture
On MarketScreener, Fresenius Medical Care is listed in the DAX family with a market capitalization of around 9.9 billion euros, and the consensus valuation multiple shows a price-earnings ratio near 12 based on current-year estimates.Finanzen.net’s analyst overview indicates that the average recommendation clusters in the Buy and Hold range, with a dividend yield of roughly 3.5 to 3.7 percent derived from recent payouts.
Analysts repeatedly identify rising treatment volumes in the United States as a central driver for a potential valuation re-rating, given the high share of the U.S. business in group earnings.Consensus data compiled by MarketScreener show expectations for gradual margin improvement as cost programs and operational adjustments feed through.
All news and analysis on the Fresenius Medical Care shares
Price charts, ad-hoc disclosures and further analyst assessments on Fresenius Medical Care can be found in the dedicated topic area.
The dialysis business behind the stock
Fresenius Medical Care generates most of its revenue with dialysis treatments and related products such as dialyzers and hemodialysis machines for patients with chronic kidney failure.The group’s company profile describes a network of thousands of dialysis centers worldwide, complemented by services ranging from patient care pathways to digital monitoring tools for nephrology practices.
Where the shares trade today
The Fresenius Medical Care shares (DE0005785802) last traded on Xetra on 2026-06-22 at 41.58 euros, based on closing data from German market platforms that recorded the four-month high referenced in broker commentary.
Key data on the Fresenius Medical Care shares
- Company: Fresenius Medical Care AG & Co. KGaA
- ISIN: DE0005785802
- WKN: 578580
- Ticker: FME
- Trading venue: Xetra
- Price (as of 2026-06-22, 17:35): 41.58 EUR
- Market cap: 9.9 billion EUR (as of 2026-06-22)
- Sector / industry: Health Care - Medical Services
- Index membership: DAX
- Next earnings date: 2026-08-01 (company guidance for early August quarterly report)
This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. All data are based on sources considered reliable but cannot be guaranteed. Investors should conduct their own research or consult a professional advisor.
